OBJECTIVES: To compare the disease status and outcomes of patients with PsA receiving adalimumab and etanercept monotherapy in Europe. METHODS: A multi-country, multi-center medical chart-review study of AS patients was conducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-identified data on patients who were recently treated with a biologic as part of usual care. Physicians were screened for duration of practice (3-30yrs) and patient volume (incl. >5PsA biologic patients/month) and recruited from a large panel to be geographically representative in each country. Eligible patient charts (≥3) were randomly selected from a sample of prospective patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status/outcomes. Patients on adalimumab/etanercept monotherapy were analyzed. RESULTS: CONCLUSIONS: Among PsA patients receiving adalimumab or etanercept monotherapy, disease severity differed within the EU5, with patients on etanercept, and patients in Italy and UK, having relatively higher burden and poorer outcomes. Factors influencing the observed patterns of geographic variation and the impact of specific biologic treatments on observed patterns warrant further scrutiny to optimize therapeutic interventions and improve outcomes.